Vaccine Formulation Strategies and Challenges Involved in RNA Delivery for Modulating Biomarkers of Cardiovascular Diseases: A Race from Laboratory to Market

Abstract

It has been demonstrated that noncoding RNAs have significant physiological and pathological roles. Modulation of noncoding RNAs may offer therapeutic approaches as per recent findings. Small RNAs, mostly long noncoding RNAs, siRNA, and microRNAs make up noncoding RNAs. Inhibiting or promoting protein breakdown by binding to 3’ untranslated regions of target mRNA, microRNAs post-transcriptionally control the pattern of gene expression. Contrarily, long non-coding RNAs perform a wider range of tasks, including serving as molecular scaffolding, decoys, and epigenetic regulators. This article provides instances of long noncoding RNAs and microRNAs that may be a biomarker of CVD (cardiovascular disease). In this paper we highlight various RNA-based vaccine formulation strategies designed to target these biomarkers—that are either currently in the research pipeline or are in the global pharmaceutical market—along with the physiological hurdles that need to be overcome.

Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends

“…This is due primarily to the complex in vivo environment, which often leads to unforeseen interactions, rendering the therapeutic ineffective or unsafe. [199] Therefore, a thorough understanding of nanoparticle behavior within biological systems is required. Moreover, there is a need to monitor the cross-reactivity of lncRNA-targeted therapeutics with other cellular components.…”

“…Despite promising results in vitro, the effectiveness of these therapeutics under physiological conditions remains uncertain. This is due primarily to the complex in vivo environment, which often leads to unforeseen interactions, rendering the therapeutic ineffective or unsafe [199] . Therefore, a thorough understanding of nanoparticle behavior within biological systems is required.…”

Role of Natural Products in Inflammatory Pharmacology: Harnessing Nature's Potential Through Drug Delivery for Therapeutic Intervention

“…Myeloid cells, including monocytes and macrophages, as well as the inhibition of Bcl6, which acts as an antagonist to NF-κB is known to have a substantial influence in coordinating the innate immune response that is accountable for the progression of atherosclerosis. This condition is characterized as a chronic inflammatory disease affecting the arterial wall [102,103]. Inflammation indeed plays a crucial role as a mediator in various processes that occur during the onset and progression of atherosclerotic disease.…”